Schulz S C, Findling R L, Friedman L, Kenny J T, Wise A L
Department of Psychiatry, Case Western Reserve University, University Hospitals of Cleveland, OH 44106, USA.
J Clin Psychiatry. 1998;59 Suppl 1:50-4; discussion 55-6.
The pharmacologic treatment and assessment of outcomes in adolescents with schizophrenia have been inadequately addressed. Structural brain imaging and brain function studies both point to a continuity between adolescent and adult stages of schizophrenia. Because the teenage population seems to be less tolerant of physical side effects, the advent of atypical antipsychotic medications may offer increased safety and efficacy. Studies support the notion that adolescent illness is associated with a more severe form of schizophrenia and that length of illness before treatment is correlated with long-term outcome. As a consequence, the authors recommend assertive pharmacologic intervention in adolescents with schizophrenia and future research focused on the issues of treatment and outcome in teenagers suffering a psychotic disorder.
青少年精神分裂症的药物治疗及疗效评估一直未得到充分关注。结构脑成像和脑功能研究均表明青少年期和成年期精神分裂症之间具有连续性。由于青少年人群似乎对身体副作用的耐受性较低，非典型抗精神病药物的出现可能会提高安全性和疗效。研究支持这样的观点，即青少年期发病的精神分裂症更为严重，且治疗前的病程长短与长期预后相关。因此，作者建议对青少年精神分裂症患者进行积极的药物干预，并建议未来的研究聚焦于患有精神障碍的青少年的治疗及预后问题。
